• V Iu Novikov, A N Kondrat'ev, N V Driagina, and R V Nazarov.
• Anesteziol Reanimatol. 2011 Jul 1 (4): 61-6.

AbstractThe aim of the study is to estimate clinical effectiveness of fibrinolysis inhibitor Tranexam in neurosurgical patients with intracranial tumors. The medication was prescribed to 78 patients from 27 to 65 years old. The control group consisted of 57 patients. The following criteria were assessed to estimate the impact of the medication on hemostasis: APPT, PT index, TT, fibrinogen, ATIII activity, factor XII-derived fibrinolysis, spontaneous euglobulin lysis. Blood sampling was drawn at the following stages: after the induction of anesthesia, before Tranexam injection, 30 minutes after Tranexam injection, on the next day after the surgery. Blood from jugular and peripheral veins was analyzed simultaneously. The medication caused significant decrease of fibrinolytic activity. The use of Tranexam was followed by bleeding reduction in the wound. The duration of surgical hemostasis in the main group was 11,7 +/- 3,3 minutes which is significantly lower than in the control group (18,1 +/- 3,1 minutes) (p = 0,034). Drainage blood loss was lower in the main group (267 +/- 23 ml a day) than in the control group (340 +/- 28 ml a day). Medication injection during diffuse bleeding from small vessels led to quick and visible bleeding reduction. Thus Tranexam decreases the risk of intraoperative blood loss in the patients with brain tumors.

21 keywords...

hide…